- Full text PDF available (7)
Adult patients with acute lymphoblastic leukemia (ALL) who are stratified into the standard-risk (SR) group due to the absence of adverse prognostic factors relapse in 40% to 55% of the cases. To identify complementary markers suitable for further treatment stratification in SR ALL, we evaluated the predictive value of minimal residual disease (MRD) and… (More)
ALL) with the Abl-tyrosine kinase inhibitor STI571 (Glivec) + leukemia (Ph Philadelphia chromosome/Bcr-Bbl positive acute lymphoblastic Early minimal residual disease (MRD) analysis during treatment of (4217 articles) Neoplasia (3667 articles) Clinical Trials and Observations Articles on similar topics can be found in the following Blood collections… (More)
In adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), minimal residual disease (MRD) after stem cell transplantation (SCT) is associated with a relapse probability exceeding 90%. Starting imatinib in the setting of MRD may decrease this high relapse rate. In this prospective multicenter study, 27 Ph+ ALL patients received… (More)
BACKGROUND Previously, we showed that glioma pathogenesis related protein (GliPR) is induced in CEM T cells upon HIV-1 infection in vitro. To examine whether GliPR plays a role as HIV dependency factor (HDF), we tested the effect of GliPR suppression by siRNA on HIV-1 replication. RESULTS Induction of GliPR expression by HIV-1 was confirmed in P4-CCR5… (More)
Early molecular response to posttransplantation imatinib determines outcome in MRD ϩ Philadelphia-positive acute lymphoblastic leukemia (Ph ϩ ALL) In adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph ؉ ALL), minimal residual disease (MRD) after stem cell transplantation (SCT) is associated with a relapse probability exceeding 90%.… (More)
Information about subscriptions and ASH membership may be found online at: .